{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:59:43Z","timestamp":1776275983862,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy plus esophagectomy; however, there remains a significant risk of distant metastasis following surgery, which compromises long-term survival among patients. The present study involved a meta-analysis designed to explore the safety and efficacy of neoadjuvant immunochemotherapy (nICT) in patients with locally advanced ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Embase, The Cochrane Library, and Web of Science were searched from inception until June 30, 2025. The extracted data included: pathological complete response (pCR), major pathological response (MPR), objective response rate (ORR),\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      resection rate, the incidence of adverse events (AEs), and \u2265 Grade 3 AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Some 30 studies with a total of 1185 patients were included, wherein the treatment regimen was nICT, without restrictions on the type of immune agents. The results showed that the MPR rate after nICT was 53% (95% confidence interval (CI): 46-59%), and the pooled pCR rate was 32% (95% CI: 29-35%). The pooled\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      resection was 97% (95% CI: 96-98%), and the pooled ORR rate was 68% (95% CI: 64-72%). The incidence of \u2265 Grade 3 treatment-related adverse events (TrAEs) was 26% (95% CI: 17-38%), the incidence of \u2265 Grade 3 surgery-related adverse events (SrAEs) was 3% (95% CI: 1-5%), and the main TrAEs in hematological toxicity were leukopenia, neutropenia, and thrombocytopenia. The main symptoms of non-hematological-toxicity TrAEs were nausea, vomiting, fatigue, decreased appetite, and rash. Infection and anastomotic fistula were the most common postoperative complications. In all, 9 cases of surgery-related deaths were identified. Among them, 3 cases were pulmonary complications (all related to pneumonia), 3 cases were direct surgery-related complications (hemorrhagic shock, anastomotic leakage complicated with hemorrhage, and esophagotracheal fistula, respectively), 1 case was severe infection, and 2 cases were attributed to unspecified causes (fatal due to surgery-related Grade V adverse events). Fatal surgical complications were uncommon.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study preliminarily indicates the efficacy and safety of nICT in locally advanced ESCC in China. This combination regimen exhibits superior pCR with tolerable safety profiles, suggesting a new therapeutic strategy for patients with locally advanced ESCC. (CRD42024574607).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024574607<\/jats:ext-link>\n                      , identifier CRD42024574607.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1687326","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:04:20Z","timestamp":1770707060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Qing","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Emergency General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailifeiya","family":"Yilixiati","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senmiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen","year":"2012","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.238","article-title":"A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study","volume":"40","author":"Kato","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0133","article-title":"Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial","volume":"156","author":"Wang","year":"2021","journal-title":"JAMA Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae083","article-title":"Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis","volume":"111","author":"Gao","year":"2024","journal-title":"Br J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo-20-599","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Shen","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.21037\/jtd-21-340","article-title":"Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma","volume":"13","author":"Wu","year":"2021","journal-title":"J Thorac Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4051","article-title":"The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study","volume":"39","author":"Zhao","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849984","article-title":"Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an open-label, single-arm study (PEN-ICE)","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.21037\/jgo-22-131","article-title":"Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)","volume":"13","author":"Gao","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1158\/1538-7445.AM2022-5230","article-title":"Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable esophageal squamous carcinoma: an open-label, single-arm study","volume":"82","author":"Jiang","year":"2022","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jncc.2022.04.002","article-title":"Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma","volume":"2","author":"Wang","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031171","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e005830","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1553","DOI":"10.1016\/j.annonc.2023.10.782","article-title":"203P Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)","volume":"34","author":"He","year":"2023","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","article-title":"Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/170265","article-title":"Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study","volume":"33","author":"Wang","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12967-023-04273-6","article-title":"Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial","volume":"21","author":"Yang","year":"2023","journal-title":"J Trans Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm-21-5381","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Trans Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer\u2014a phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482005","article-title":"Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12604","article-title":"Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.21037\/jtd-2025-215","article-title":"Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma","volume":"17","author":"Wang","year":"2025","journal-title":"J Thorac Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.11.134","article-title":"Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet","volume":"48","author":"Sui","year":"2025","journal-title":"Asian J Surg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1486275","article-title":"Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00262-025-04099-9","article-title":"Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma","volume":"74","author":"Deng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02805-5","article-title":"Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial","volume":"131","author":"Chen","year":"2024","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7076","article-title":"Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis","volume":"13","author":"Gaber","year":"2024","journal-title":"Cancer Medicine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-A phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.0220","article-title":"Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma","volume":"160","author":"Guo","year":"2025","journal-title":"JAMA Surg"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00464-025-12166-6","article-title":"Impact of clinical decisions on patient outcomes after neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma","volume":"39","author":"Huang","year":"2025","journal-title":"Surg Endosc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00027-0","article-title":"Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial","volume":"26","author":"van der Wilk","year":"2025","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-017-3548-1","article-title":"Optimal therapy in locally advanced esophageal cancer: a national cancer database analysis","volume":"22","author":"Whited","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"B56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102334","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1+ CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102554","DOI":"10.1016\/j.tranon.2025.102554","article-title":"Expression of ORMDL1 in esophageal squamous cell carcinoma and its effect on patient outcomes: A potential biomarker and treatment target","volume":"62","author":"Wang","year":"2025","journal-title":"Trans Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1687326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:04:22Z","timestamp":1770707062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1687326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2026.1687326"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1687326","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1687326"}}